Triazol: a privileged scaffold for proteolysis targeting chimeras

Papers of special note have been highlighted as : • of interest

References

• 1. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237 (2012).
  Medline CASGoogle Scholar
• 2. Jemal A, Clegg LX, Ward E et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 101(1), 3–27 (2004).
  MedlineGoogle Scholar
• 3. Morrow JK, Lin H-K, Sun S-C, Zhang S. Targeting ubiquitination for cancer therapies. Future Med. Chem. 7(17), 2333–2350 (2015).
  CASGoogle Scholar
• 4. Kumar A, Singh UK, Chaudhary A. Targeting autophagy to overcome drug resistance in cancer therapy. Future Med. Chem. 7(12), 1535–1542 (2015).
  CASGoogle Scholar
• 5. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A. Cancer J. Clin. 61(2), 69–90 (2011).
  MedlineGoogle Scholar
• 6. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA: A. Cancer J. Clin. 49(1), 33–64 (1999).
  Medline CASGoogle Scholar
• 7. Molin Y, Fayette J. Current chemotherapies for recurrent/metastatic head and neck cancer. Anticancer Drugs 22(7), 621–625 (2011).
  Medline CASGoogle Scholar
• 8. Dang CV, Reddy EP, Shokat KM, Soucek L. Drugging the ‘undruggable’ cancer targets. Nat. Rev. Cancer 17(8), 502–508 (2017).
  Medline CASGoogle Scholar
• 9. Lazo JS, Sharlow ER. Drugging undruggable molecular cancer targets. Annu. Rev. Pharmacol. Toxicol. 56(1), 23–40 (2016).
  Medline CASGoogle Scholar
• 10. Arkin MR, Wells JA. Small-molecule inhibitors of protein–protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3, 301 (2004).
  Medline CASGoogle Scholar
• 11. Tol J, Punt CJA. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin. Ther. 32(3), 437–453 (2010).
  Medline CASGoogle Scholar
• 12. Deng Y, Wang CC, Choy KW et al. Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 538(2), 217–227 (2014).
  Medline CASGoogle Scholar
• 13. Clegg MA, Tomkinson NC, Prinjha RK, Humphreys PG. Small molecules and their role in effective preclinical target validation. Future Med. Chem. 9(14), 1579–1582 (2017).
  CASGoogle Scholar
• 14. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714 (2013).
  Medline CASGoogle Scholar
• 15. Nobili S, Galletta A, Brugia M et al. Emerging drugs in refractory colorectal cancer. Future Med. Chem. 7(12), 1491–1501 (2015).
  CASGoogle Scholar
• 16. Xie L, Xie L, Bourne PE. Structure-based systems biology for analyzing off-target binding. Curr. Opin. Struc. Biol. 21(2), 189–199 (2011).
  Medline CASGoogle Scholar
• 17. Mei Y, Yang B. Rational application of drug promiscuity in medicinal chemistry. Future Med. Chem. 10(15), 1835–1851 (2018).
  CASGoogle Scholar
• 18. Joubert N, Denevault-Sabourin C, Bryden F, Viaud-Massuard M-C. Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy. Eur. J. Med. Chem. 142, 393–415 (2017).
  Medline CASGoogle Scholar
• 19. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147 (2005).
  Medline CASGoogle Scholar
• 20. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 9, 767 (2010).
  Medline CASGoogle Scholar
• 21. Hannon GJ. RNA interference. Nature 418(6894), 244–251 (2002).
  Medline CASGoogle Scholar
• 22. Mello CC, Conte D. Revealing the world of RNA interference. Nature 431(7006), 338–342 (2004).
  Medline CASGoogle Scholar
• 23. Ge Q, Xu JJ, Evans DM, Mixson AJ, Yang HY, Lu PY. Leveraging therapeutic potential of multi-targeted siRNA inhibitors. Future Med. Chem. 1(9), 1671–1681 (2009).
  CASGoogle Scholar
• 24. El-Daly SM, Abba ML, Gamal-Eldeen AM. The role of microRNAs in photodynamic therapy of cancer. Eur. J. Med. Chem. 142, 550–555 (2017).
  Medline CASGoogle Scholar
• 25. Maiti S, Paira P. Biotin conjugated organic molecules and proteins for cancer therapy: a review. Eur. J. Med. Chem. 145, 206–223 (2018).
  Medline CASGoogle Scholar
• 26. Nalepa G, Rolfe M, Harper JW. Drug discovery in the ubiquitin–proteasome system. Nat. Rev. Drug Discov. 5, 596 (2006).
  Medline CASGoogle Scholar
• 27. Hershko A, Heller H, Elias S, Ciechanover A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J. Biol. Chem. 258(13), 8206–8214 (1983).
  Medline CASGoogle Scholar
• 28. Pickart CM. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70(1), 503–533 (2001).
  Medline CASGoogle Scholar
• 29. An S, Fu L. Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs. EBioMedicine 36, 553–562 (2018).
  MedlineGoogle Scholar
• 30. Churcher I. Protac-induced protein degradation in drug discovery: breaking the rules or just making new ones? J. Med. Chem. 61(2), 444–452 (2018).
  Medline CASGoogle Scholar
• 31. Zou Y, Ma D, Wang Y. The PROTAC technology in drug development. Cell Biochem. Funct. 37(1), 21–30 (2019).
  Medline CASGoogle Scholar
• 32. Bondeson DP, Smith BE, Burslem GM et al. Lessons in PROTAC design from selective degradation with a promiscuous warhead. Cell Chem. Biol. 25(1), 78–87.e75 (2018).
  Medline CASGoogle Scholar
• 33. Toure M, Crews CM. Small-molecule PROTACS: new approaches to protein degradation. Angew. Chem. Int. Edit. 55(6), 1966–1973 (2016).
  Medline CASGoogle Scholar
• 34. Qi J, Zhang G. Proteolysis-targeting chimeras for targeting protein for degradation. Future Med. Chem. 11(7), 723–741 (2019).
  CASGoogle Scholar
• 35. Tiwari VK, Mishra BB, Mishra KB, Mishra N, Singh AS, Chen X. Cu-catalyzed click reaction in carbohydrate chemistry. Chem. Rev. 116(5), 3086–3240 (2016).
  Medline CASGoogle Scholar
• 36. Gholampour M, Ranjbar S, Edraki N, Mohabbati M, Firuzi O, Khoshneviszadeh M. Click chemistry assisted synthesis of novel aminonaphthoquinone-1,2,3-triazole hybrids and investigation of their cytotoxicity and cancer cell cycle alterations. Bioorg. Chem. 88, 102967 (2019).
  Medline CASGoogle Scholar
• 37. Moses JE, Moorhouse AD. The growing applications of click chemistry. Chem. Soc. Rev. 36(8), 1249–1262 (2007).
  Medline CASGoogle Scholar
• 38. Dheer D, Singh V, Shankar R. Medicinal attributes of 1,2,3-triazoles: current developments. Bioorg. Chem. 71, 30–54 (2017).
  Medline CASGoogle Scholar
• 39. Valeur E, Guéret SM, Adihou H et al. New modalities for challenging targets in drug discovery. Angew. Chem. Int. Edit. 56(35), 10294–10323 (2017).
  Medline CASGoogle Scholar
• 40. Gu S, Cui D, Chen X, Xiong X, Zhao Y. PROTACs: an emerging targeting technique for protein degradation in drug discovery. BioEssays 40(4), e1700247 (2018).
  MedlineGoogle Scholar
• 41. Wang P, Zhou J. Proteolysis targeting chimera (PROTAC): a paradigm-shifting approach in small molecule drug discovery. Curr. Top. Med. Chem. 18(16), 1354–1356 (2018).
  Medline CASGoogle Scholar
• 42. Pettersson M, Crews CM. PROteolysis TArgeting Chimeras (PROTACs) – past, present and future. Drug Discov. Today: Technol. 31(1), 15–27 (2019).
  Google Scholar
• 43. Salami J, Crews CM. Waste disposal—an attractive strategy for cancer therapy. Science 355(6330), 1163–1167 (2017). • The first peptide-based PROteolysis TArgeting Chimeras (PROTACs) were present in this paper.
  Medline CASGoogle Scholar
• 44. Sakamoto KM, Kim KB, Kumagai A, Mercurio F, Crews CM, Deshaies RJ. Protacs: chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation. Proc. Natl Acad. Sci. USA 98(15), 8554–8559 (2001).
  Medline CASGoogle Scholar
• 45. Sakamoto KM, Kim KB, Verma R et al. Development of protacs to target cancer-promoting proteins for ubiquitination and degradation. Mol. Cell. Proteomics 2(12), 1350–1358 (2003). • The first cell-permeable PROTACs were reported in this paper.
  Medline CASGoogle Scholar
• 46. Zhang D, Baek S-H, Ho A, Kim K. Degradation of target protein in living cells by small-molecule proteolysis inducer. Bioorg. Med. Chem. Lett. 14(3), 645–648 (2004).
  Medline CASGoogle Scholar
• 47. Rodriguez-Gonzalez A, Cyrus K, Salcius M et al. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene 27, 7201 (2008).
  Medline CASGoogle Scholar
• 48. Schneekloth JS, Fonseca FN, Koldobskiy M et al. Chemical genetic control of protein levels: selective in vivo targeted degradation. J. Am. Chem. Soc. 126(12), 3748–3754 (2004).
  Medline CASGoogle Scholar
• 49. Bondeson DP, Mares A, Smith IED et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611 (2015).
  Medline CASGoogle Scholar
• 50. Buckley DL, Crews CM. Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. Angew. Chem. Int. Edit. 53(9), 2312–2330 (2014).
  Medline CASGoogle Scholar
• 51. Crews CM. Targeting the undruggable proteome: the small molecules of my dreams. Chem. Biol. 17(6), 551–555 (2010). • The first small-molecule PROTACs were present in this paper.
  Medline CASGoogle Scholar
• 52. Schneekloth AR, Pucheault M, Tae HS, Crews CM. Targeted intracellular protein degradation induced by a small molecule: en route to chemical proteomics. Bioorg. Med. Chem. Lett. 18(22), 5904–5908 (2008).
  Medline CASGoogle Scholar
• 53. Itoh Y, Ishikawa M, Naito M, Hashimoto Y. Protein knockdown using methyl bestatin−ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins. J. Am. Chem. Soc. 132(16), 5820–5826 (2010).
  Medline CASGoogle Scholar
• 54. Dueber EC, Schoeffler AJ, Lingel A et al. Antagonists induce a conformational change in cIAP1 that promotes autoubiquitination. Science 334(6054), 376–380 (2011).
  Medline CASGoogle Scholar
• 55. Okuhira K, Ohoka N, Sai K et al. Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein. FEBS Lett. 585(8), 1147–1152 (2011).
  Medline CASGoogle Scholar
• 56. Ohoka N, Nagai K, Hattori T et al. Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin–proteasome pathway. Cell Death Dis. 5, e1513 (2014).
  Medline CASGoogle Scholar
• 57. Okuhira K, Demizu Y, Hattori T et al. Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells. Cancer Sci. 104(11), 1492–1498 (2013).
  Medline CASGoogle Scholar
• 58. Demizu Y, Shibata N, Hattori T et al. Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand. Bioorg. Med. Chem. Lett. 26(20), 4865–4869 (2016).
  Medline CASGoogle Scholar
• 59. Zengerle M, Chan K-H, Ciulli A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem. Biol. 10(8), 1770–1777 (2015).
  Medline CASGoogle Scholar
• 60. Raina K, Lu J, Qian Y et al. PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 113(26), 7124–7129 (2016). • The first administered PROTAC in a Phase I clinical trial is reported in this paper.
  Medline CASGoogle Scholar
• 61. Kargbo RB. Treatment of prostate cancers and Kennedy's disease by PROTAC-androgen receptor degradation. ACS Med. Chem. Lett. 10(5), 701–702 (2019).
  Medline CASGoogle Scholar
• 62. Zhou B, Hu J, Xu F et al. Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J. Med. Chem. 61(2), 462–481 (2018). • The first in vivo PROTACs technology is reported in this paper.
  Medline CASGoogle Scholar
• 63. Hines J, Gough JD, Corson TW, Crews CM. Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs. Proc. Natl Acad. Sci. USA 110(22), 8942–8947 (2013).
  Medline CASGoogle Scholar
• 64. Sun X, Wang J, Yao X et al. A chemical approach for global protein knockdown from mice to non-human primates. Cell Discov. 5(1), 10 (2019).
  MedlineGoogle Scholar
• 65. Fischer ES, Böhm K, Lydeard JR et al. Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide. Nature 512, 49 (2014).
  Medline CASGoogle Scholar
• 66. Ito T, Ando H, Suzuki T et al. Identification of a primary target of thalidomide teratogenicity. Science 327(5971), 1345–1350 (2010).
  Medline CASGoogle Scholar
• 67. Winter GE, Buckley DL, Paulk J et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348(6241), 1376–1381 (2015).
  Medline CASGoogle Scholar
• 68. Lu J, Qian Y, Altieri M et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22(6), 755–763 (2015). • The first in-cell click formed PROTACs are reported in this paper.
  Medline CASGoogle Scholar
• 69. Lebraud H, Wright DJ, Johnson CN, Heightman TD. Protein degradation by in-cell self-assembly of proteolysis targeting chimeras. ACS Central Sci. 2(12), 927–934 (2016).
  Medline CASGoogle Scholar
• 70. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. Drug Discov. Today 8(24), 1128–1137 (2003).
  Medline CASGoogle Scholar
• 71. Sayeed IB, Vishnuvardhan MVPS, Nagarajan A, Kantevari S, Kamal A. Imidazopyridine linked triazoles as tubulin inhibitors, effectively triggering apoptosis in lung cancer cell line. Bioorg. Chem. 80, 714–720 (2018).
  Medline CASGoogle Scholar
• 72. Rodionov VO, Fokin VV, Finn MG. Mechanism of the ligand-free CuI-catalyzed azide–alkyne cycloaddition reaction. Angew. Chem. Int. Edit. 44(15), 2210–2215 (2005).
  Medline CASGoogle Scholar
• 73. Worrell BT, Malik JA, Fokin VV. Direct evidence of a dinuclear copper intermediate in Cu(I)-catalyzed azide-alkyne cycloadditions. Science 340(6131), 457–460 (2013).
  Medline CASGoogle Scholar
• 74. Gadd MS, Testa A, Lucas X et al. Structural basis of PROTAC cooperative recognition for selective protein degradation. Nat. Chem. Biol. 13, 514 (2017). • The first comprehensive study on PROTACs with triazole linker was reported in this paper.
  Medline CASGoogle Scholar
• 75. Wurz RP, Dellamaggiore K, Dou H et al. A “click chemistry platform” for the rapid synthesis of bispecific molecules for inducing protein degradation. J. Med. Chem. 61(2), 453–461 (2018).
  Medline CASGoogle Scholar
• 76. Schiedel M, Herp D, Hammelmann S et al. Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals). J. Med. Chem. 61(2), 482–491 (2018).
  Medline CASGoogle Scholar
• 77. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673 (2014).
  Medline CASGoogle Scholar
• 78. Sangwan R, Rajan R, Mandal PK. HDAC as onco target: reviewing the synthetic approaches with SAR study of their inhibitors. Eur. J. Med. Chem. 158, 620–706 (2018).
  Medline CASGoogle Scholar
• 79. Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med. Chem. 4(11), 1439–1460 (2012).
  CASGoogle Scholar
• 80. Yang K, Song Y, Xie H et al. Development of the first small molecule histone deacetylase 6 (HDAC6) degraders. Bioorg. Med. Chem. Lett. 28(14), 2493–2497 (2018).
  Medline CASGoogle Scholar
• 81. An Z, Lv W, Su S, Wu W, Rao Y. Developing potent PROTACs tools for selective degradation of HDAC6 protein. Protein Cell doi:10.1007/s13238-019-0613-4 (2019) (Epub ahead of print).
  Google Scholar
• 82. Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton's tyrosine kinase in B cell malignancies. Nat. Rev. Cancer 14, 219 (2014).
  Medline CASGoogle Scholar
• 83. Liang C, Tian D, Ren X et al. The development of Bruton‘s tyrosine kinase (BTK) inhibitors from 2012 to 2017: a mini-review. Eur. J. Med. Chem. 151, 315–326 (2018).
  Medline CASGoogle Scholar
• 84. Liu L, Shi B, Wang X, Xiang H. Strategies to overcome resistance mutations of Bruton‘s tyrosine kinase inhibitor ibrutinib. Future Med. Chem. 10(3), 343–356 (2018).
  CASGoogle Scholar
• 85. Macias-Perez IM, Flinn IW. B-cell receptor pathobiology and targeting in NHL. Curr. Oncol. Rep. 14(5), 411–418 (2012).
  Medline CASGoogle Scholar
• 86. Sun Y, Zhao X, Ding N et al. PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res. 28(7), 779–781 (2018).
  Medline CASGoogle Scholar
• 87. Sun Y, Ding N, Song Y et al. Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia 33(8), 2105–2110 (2019).
  MedlineGoogle Scholar
• 88. Tinworth CP, Lithgow H, Dittus L et al. PROTAC-mediated degradation of Bruton's tyrosine kinase is inhibited by covalent binding. ACS Chem. Biol. 14(3), 342–347 (2019).
  Medline CASGoogle Scholar
• 89. Bian JL, Ren J, Li YR et al. Discovery of Wogonin-based PROTACs against CDK9 and capable of achieving antitumor activity. Bioorg. Chem. 81, 373–381 (2018).
  Medline CASGoogle Scholar
• 90. Zhao B, Burgess K. PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer. Chem. Commun. 55(18), 2704–2707 (2019).
  Medline CASGoogle Scholar
• 91. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20, 3247 (2001).
  Medline CASGoogle Scholar
• 92. Seldin D, Leder P. Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 267(5199), 894–897 (1995).
  Medline CASGoogle Scholar
• 93. Chen H, Chen F, Liu N, Wang X, Gou S. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin–proteasome pathway. Bioorganic Chem. 81, 536–544 (2018).
  Medline CASGoogle Scholar
• 94. Zhao Q, Lan T, Su S, Rao Y. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule. Chem. Commun. 55(3), 369–372 (2019).
  Medline CASGoogle Scholar
• 95. Jagtap P, Szabó C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Discov. 4, 421 (2005).
  Medline CASGoogle Scholar
• 96. Jain PG, Patel BD. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - a recent update. Eur. J. Med. Chem. 165, 198–215 (2019).
  Medline CASGoogle Scholar
• 97. Kumar C, Rani N, Lakshmi PTV, Arunachalam A. A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy. Future Med. Chem. 9(1), 37–60 (2017).
  CASGoogle Scholar
• 98. Neklesa TK, Crews CM. Greasy tags for protein removal. Nature 487, 308 (2012).
  Medline CASGoogle Scholar
• 99. Rubner S, Schubert S, Berg T. Poloxin-2HT+: changing the hydrophobic tag of Poloxin-2HT increases Plk1 degradation and apoptosis induction in tumor cells. Org. Biomol. Chem. 17(12), 3113–3117 (2019).
  Medline CASGoogle Scholar
• 100. Normandin K, Lavallée J-F, Futter M et al. Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay. Sci. Rep. 6, 37581 (2016).
  Google Scholar
• 101. Scharow A, Raab M, Saxena K et al. Optimized Plk1 PBD inhibitors based on poloxin induce mitotic arrest and apoptosis in tumor cells. ACS Chem. Biol. 10(11), 2570–2579 (2015).
  Medline CASGoogle Scholar